desipramine has been researched along with Chemical and Drug Induced Liver Injury in 15 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We present two cases of myocarditis and hepatitis with histologic characteristics of hypersensitivity-mediated drug reactions associated with imipramine and its metabolite, desipramine." | 7.67 | Hypersensitivity myocarditis and hepatitis associated with imipramine and its metabolite, desipramine. ( Bonadies, J; Hardin, NJ; Morrow, PL, 1989) |
| "We present two cases of myocarditis and hepatitis with histologic characteristics of hypersensitivity-mediated drug reactions associated with imipramine and its metabolite, desipramine." | 3.67 | Hypersensitivity myocarditis and hepatitis associated with imipramine and its metabolite, desipramine. ( Bonadies, J; Hardin, NJ; Morrow, PL, 1989) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (40.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greene, N | 1 |
| Fisk, L | 1 |
| Naven, RT | 1 |
| Note, RR | 1 |
| Patel, ML | 1 |
| Pelletier, DJ | 1 |
| Morgan, RE | 2 |
| Trauner, M | 1 |
| van Staden, CJ | 2 |
| Lee, PH | 1 |
| Ramachandran, B | 1 |
| Eschenberg, M | 1 |
| Afshari, CA | 2 |
| Qualls, CW | 1 |
| Lightfoot-Dunn, R | 1 |
| Hamadeh, HK | 2 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Warner, DJ | 1 |
| Chen, H | 1 |
| Cantin, LD | 1 |
| Kenna, JG | 1 |
| Stahl, S | 1 |
| Walker, CL | 1 |
| Noeske, T | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Price, LH | 2 |
| Nelson, JC | 2 |
| Jatlow, PI | 1 |
| Waltrip, RW | 1 |
| Remy, AJ | 1 |
| Larrey, D | 1 |
| Pageaux, GP | 1 |
| Ribstein, J | 1 |
| Ramos, J | 1 |
| Michel, H | 1 |
| Morrow, PL | 1 |
| Hardin, NJ | 1 |
| Bonadies, J | 1 |
| Hoge, SK | 1 |
| Biederman, J | 1 |
| Powell, WJ | 1 |
| Koch-Weser, J | 1 |
| Williams, RA | 1 |
| Mitchell, JR | 1 |
| Thorgeirsson, SS | 1 |
| Potter, WZ | 1 |
| Jollow, DJ | 1 |
| Keiser, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00799578] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00799578)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Number of Improved Subjects | 7 |
1 review available for desipramine and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
14 other studies available for desipramine and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Effects of desipramine on clinical liver function tests.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Depressive Disorder; Desipramine; Dose-Response | 1984 |
Desipramine-associated hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Depressive Disorder; Desipramine; Female; Humans; Liv | 1983 |
Cross hepatotoxicity between tricyclic antidepressants and phenothiazines.
Topics: Aged; Antidepressive Agents, Tricyclic; Chemical and Drug Induced Liver Injury; Desipramine; Female; | 1995 |
Hypersensitivity myocarditis and hepatitis associated with imipramine and its metabolite, desipramine.
Topics: Aged; Chemical and Drug Induced Liver Injury; Desipramine; Drug Hypersensitivity; Female; Humans; Im | 1989 |
Liver function tests during treatment with desipramine in children and adolescents.
Topics: Adolescent; Alkaline Phosphatase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injur | 1987 |
Lethal hepatic necrosis after therapy with imipramine and desipramine.
Topics: Aged; Chemical and Drug Induced Liver Injury; Dermatitis, Exfoliative; Desipramine; Drug Hypersensit | 1968 |
Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy.
Topics: Acetaminophen; Acetylcysteine; Adult; Amobarbital; Animals; Chemical and Drug Induced Liver Injury; | 1974 |